


PANBIO™ COVID-19 TESTS AND EMERGING VARIANTS

No Predicted Impact of the Omicron Variant on Panbio™ COVID-19 Ag Rapid Test Device, Panbio™ COVID-19 Antigen Self-Test, and Panbio™ COVID-19 IgG/IgM Rapid Test Device Based on *In Silico* Analysis¹

Abbott is continuously monitoring the global SARS-CoV-2 situation through complex processes overseen by the Abbott Pandemic Defense Coalition.^{2,3}



THERE IS NO PREDICTED IMPACT ON PANBIO™ COVID-19 ANTIGEN AND ANTIBODY TEST PERFORMANCE BY ANY OF THESE VARIANTS ANALYZED AS OF NOVEMBER 26, 2021, INCLUDING THE OMICRON VARIANT:

WHO NOMENCLATURE	LINEAGE	COUNTRY FIRST DETECTED
ALPHA	B.1.1.7	ENGLAND, UK
BETA	B.1.351	SOUTH AFRICA
BETA	B.1.351.2	SOUTH AFRICA
BETA	B.1.351.3	SOUTH AFRICA
GAMMA	P.1	JAPAN EX MANAUS, BRAZIL
GAMMA	P.1.1	BRAZIL
GAMMA	P.1.2	BRAZIL
DELTA*	B.1.617.2	INDIA
DELTA*	AY.1	INDIA
DELTA*	AY.2	INDIA
DELTA*	AY.3	INDIA
DELTA*	AY.3.1	USA
DELTA*	AY.4	NOT CONFIRMED
DELTA*	AY.5	NOT CONFIRMED
DELTA*	AY.6	THAILAND
DELTA*	AY.7	INDIA
DELTA*	AY.8	NOT CONFIRMED
DELTA*	AY.9	INDIA
DELTA*	AY.10	NOT CONFIRMED
DELTA*	AY.11	NOT CONFIRMED
DELTA*	AY.12	NOT CONFIRMED

WHO NOMENCLATURE	LINEAGE	COUNTRY FIRST DETECTED
EPSILON	B.1.427	CALIFORNIA, USA
EPSILON	B.1.429	CALIFORNIA, USA
ZETA	P.2	BRAZIL
ETA	B.1.525	ENGLAND, UK, NIGERIA
THETA	P.3	PHILIPPINES
IOTA	B.1.526	NEW YORK, USA
KAPPA	B.1.617.1	INDIA
LAMBDA	C.37	PERU
MU	B.1.621	COLOMBIA
MU	B.1.621.1	NOT CONFIRMED
OMICRON	B.1.1.529	MULTIPLE COUNTRIES
NOT DESIGNATED	A.23.1+E484K	ENGLAND, UK
NOT DESIGNATED	A.27	NOT CONFIRMED
NOT DESIGNATED	AT.1	RUSSIA
NOT DESIGNATED	AV.1	ENGLAND, UK
NOT DESIGNATED	B.1.1.318	ENGLAND, UK



WHO NOMENCLATURE	LINEAGE	COUNTRY FIRST DETECTED
NOT DESIGNATED	B.1.1.519	MEXICO
NOT DESIGNATED	B.1.1.523	NOT CONFIRMED
NOT DESIGNATED	B.1.1.7 WITH E484K	ENGLAND, UK
NOT DESIGNATED	B.1.214.2	NOT CONFIRMED
NOT DESIGNATED	B.1.429.1	NOT CONFIRMED
NOT DESIGNATED	B.1.466.2	INDONESIA
NOT DESIGNATED	B.1.526.1	NEW YORK, USA
NOT DESIGNATED	B.1.526.2	NEW YORK, USA
NOT DESIGNATED	B.1.616	FRANCE

WHO NOMENCLATURE	LINEAGE	COUNTRY FIRST DETECTED
NOT DESIGNATED	B.1.617.3	INDIA
NOT DESIGNATED	B.1.618	INDIA
NOT DESIGNATED	B.1.619	NOT CONFIRMED
NOT DESIGNATED	B.1.620	NOT CONFIRMED
NOT DESIGNATED	B.1.628	NOT CONFIRMED
NOT DESIGNATED	C.1.2	SOUTH AFRICA
NOT DESIGNATED	C.36.3	NOT CONFIRMED
NOT DESIGNATED	C.36.3.1	NOT CONFIRMED
NOT DESIGNATED	R.1	JAPAN AND USA

Abbott will continue to publish evaluations as emerging variants continue to arise.

Product not available in all countries. Available to consumers in select markets. Not all products approved for sale in the U.S.

* Includes all AY lineages, which as noted by the WHO, is an alias for B.1.617.2 in Pango nomenclature.^{4,5}

- <https://www.abbott.com/corpnnewsroom/diagnostics-testing/monitoring-covid-variants-to-ensure-test-effectiveness.html>
- <https://abbott.mediaroom.com/2021-03-11-Abbott-Announces-its-Pandemic-Defense-Coalition-A-Global-Network-of-Expert-Collaborators-Designed-To-Help-Prevent-Future-Pandemics-Currently-Searching-for-COVID-19-Variants>
- <https://www.abbott.com/corpnnewsroom/products-and-innovation/how-we-track-covid-19-variants.html>
- <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> (Accessed 11/30/2021)
- <http://pango.network/new-ay-lineages/> (Accessed 11/30/2021)

© 2021 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. COL-09037-01 11/21

